VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Reidy-Lagunes on Determining the Site of Unknown Primary in Metastatic NETs

Diane Reidy-Lagunes, MD
Published: Friday, Oct 10, 2014

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis looking at a practical method of determining the site of unknown primary in metastatic neuroendocrine tumors (NETs). This was presented by Jessica E. Maxwell, MD, MBA, from the University of Iowa, at a clinical science symposium at the 2014 NANETS Symposium.

Approximately 20% of patients with NETs have an unknown primary. In this analysis, an algorithm involving gene and protein expression was created from over 100 metastases from known small bowl and pancreatic primaries. With over 90% accuracy, researchers were able to evaluate immunohistochemistry, define small bowel or pancreatic NETs by pathology, and confirm it with genetic testing.

This method has not yet been validated with unknown primaries.

<<< View more from NANETS

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis looking at a practical method of determining the site of unknown primary in metastatic neuroendocrine tumors (NETs). This was presented by Jessica E. Maxwell, MD, MBA, from the University of Iowa, at a clinical science symposium at the 2014 NANETS Symposium.

Approximately 20% of patients with NETs have an unknown primary. In this analysis, an algorithm involving gene and protein expression was created from over 100 metastases from known small bowl and pancreatic primaries. With over 90% accuracy, researchers were able to evaluate immunohistochemistry, define small bowel or pancreatic NETs by pathology, and confirm it with genetic testing.

This method has not yet been validated with unknown primaries.

<<< View more from NANETS


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x